Formycon reports nine-month results for 2024 and continues growth trajectory with further operational success Excellent third quarter with product approvals for FYB202 in the key markets USA and ...
Month figures/Quarterly / Interim StatementFormycon reports nine-month results for 2024 and continues growth trajectory with further operational successes 28.11.2024 / 06:30 CET/CESTThe issuer is ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback